放射肿瘤学综合临床质量保证系统的实施
该研究开发并评估了苏黎世放射肿瘤学临床质量保证系统(ZH-CLASSIC),并以局限期前列腺癌根治性立体定向放疗为首个用例验证随访系统。系统自2021年5月起管理4515例患者,医生数据填报依从性从2021年均值54%升至2024年92%。209例前列腺癌患者行MRIdian每日在线自适应SBRT后中位随访15个月,208/209存活,报告CTCAE≥2级泌尿毒性13%、胃肠毒性3%。
要点
- ZH-CLASSIC实现指征、治疗与结局的自动化结构化文档与分析
- 医生填报依从性由2021年54%升至2024年92%
- 前列腺癌SBRT后中位随访15个月,208/209例存活
核心结论
- ZH-CLASSIC系统可对放射肿瘤患者的指征、治疗和结局质量进行自动化结构化文档与分析。
- 局限期前列腺癌SBRT分析结果与文献报告值一致,验证了随访系统的可行性。
研究设计与样本
- 本研究为质量保证系统开发与评估项目,以局限期前列腺癌根治性SBRT为首个用例。
- 系统数据自动取自医院信息系统、放射肿瘤记录与验证系统及专用随访数据库,以唯一患者ID合并。
- 以十条患者诊疗路径为基础进行数据汇总、持续分析与报告,覆盖放疗指征、治疗及不同随访方式。
- 随访系统验证纳入≥18岁、cT1-3 cN0 cM0前列腺癌患者,接受根治性原发立体定向放疗。
主要发现
- 自2021年5月起ZH-CLASSIC共管理4515例患者。
- 医生填报数据依从性从2021年均值54%升至2024年92%。
- 所有患者随访方式为门诊51%、电话7%、外部查询43%,缺失信息5%中96%源于外部请求。
- 前列腺癌患者(n=209)行MRIdian每日在线自适应SBRT,方案为5×7.25 Gy隔日或5×7.5 Gy每周。
- 中位随访15个月(范围6-41个月)时208/209例存活,CTCAE泌尿2级12%、3级1%,胃肠2级3%、3级0%。
关键数值与推荐
- 随访系统验证人群标准:≥18岁、cT1-3 cN0 cM0前列腺癌,接受根治性原发立体定向放疗。
- SBRT方案:MRIdian每日在线自适应,5×7.25 Gy隔日或5×7.5 Gy每周。
- 毒性按CTCAE报告:泌尿2级12%、3级1%;胃肠2级3%、3级0%。
- 人员资源:实施前一年0.75 FTE项目经理,持续支出0.13 FTE医生和1.00 FTE随访管理员。
临床怎么用
- 可参考ZH-CLASSIC以十条诊疗路径为基础整合医院信息系统、记录验证系统与随访数据库。
- 系统启动期需专职人员,但人力投入预期持续下降。
- 随访可结合门诊、电话与外部查询,需注意外部请求是信息缺失的主要来源。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The objective of this project was to develop and evaluate a comprehensive clinical quality assurance system for radiation oncology, and assess the system using definitive radiation therapy for prostate cancer as a first use case. METHODS: The Zurich Clinical Quality Assurance System in Radiation Oncology (ZH-CLASSIC) was initiated to allow for continuous quality assurance in radiation oncology with respect to indication for radiation therapy, practice of radiation therapy and patient outcome. Data from the sources of the hospital information system, the Radiation Oncology Record and Verify System and a dedicated follow-up database were automatically retrieved, and combined using a unique patient-ID. Data aggregation, continuous analysis and reporting was performed using ten distinct patient care pathways as the basis which covers all aspects of radiation therapy treatments and indications as well as the different follow-up schemes (in-clinic, telemedicine, and external follow-up). The follow-up system was validated through analysis of patients with prostate cancer (≥ 18 years, cT1-3 cN0 cM0) who underwent curative, primary stereotactic radiation therapy. Survival, treatment effectiveness, tumor control, acute and late toxicity, and performance status were analyzed. RESULTS: Since May 2021, a total of 4,515 individual patients were being managed in ZH-CLASSIC. Personal resources amounted to 0.75 full time equivalent (FTE) project manager for one year prior to implementation, 0.13 FTE physician and 1.00 FTE follow-up manager as ongoing expenses. Compliance with respect to reporting data into ZH-CLASSIC by the physicians increased from a mean of 54% in 2021 to 92% in 2024. For all patients, follow-up was performed as in-clinic visits (51%), via telephone (7%) or as an external query (43%), with missing information (5%) originating from external requests in 96%. Instead of an intended first in-clinic follow-up visit, telemedicine appointments were conducted in 10% and external follow-ups were performed in 22%. Oncological outcomes and toxicities were evaluated for all prostate cancer patients (n = 209) treated with daily online-adaptive SBRT on the MRIdian using 5 × 7.25 Gy every other day or 5 × 7.5 Gy weekly. After a median follow-up of 15 months (range, 6-41 months), 208/209 patients were alive. Over this time period, reported CTCAE toxicities included genitourinary grade 2: 12%, grade 3: 1%, and gastrointestinal grade 2: 3%, grade 3: 0%. CONCLUSIONS: The ZH-CLASSIC system allowed for automated and structured documentation and analysis of the quality with regards to the indication, treatment and outcome of radio-oncological cancer patients. Dedicated staff are needed in the start-up period but personal resources are expected to continuously decrease. Analyses of patients treated with SBRT for localized prostate cancer resulted in plausible results in agreement with reported values in the literature. CLINICAL TRIAL NUMBER: Not applicable.
引用
- Joye AA, Zosso-Pavic M, Beckmann J, et al. Implementation of a comprehensive clinical quality assurance system in radiation oncology. Radiat Oncol. 2025. PMID: 40312685. doi:10.1186/s13014-025-02633-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。